Equity Research Medical Care Facilities

Should You Buy Chemed Corp Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Chemed Corp (CHE) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 9.1/10. At a current price of $510.42 and a market capitalization of $6.8B, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.

The short answer: 1 of 12 CirclFi valuation models project upside for Chemed Corp (CHE) at $510.42 — the model consensus leans bearish, with a Quality Score of 9.1/10 and Value-Trap risk of 21/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 11 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 9.1/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 21/100 — Minimal — healthy fundamentals
  • Fair Value Range: $12.38 – $601.42 (4758% spread)

Bullish Models

1 / 12

Bearish Models

11 / 12

Quality Score

9.1 /10

Excellent — top-tier fundamentals

Value Trap Risk

21 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 47%

Investment Thesis

The Bull Case

Target: $601.42 (+17.8% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Chemed Corp's score of 9.1/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $601.42 (+17.8%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.

The Bear Case

Target: $12.38 (-97.6%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $12.38 (-97.6%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +115.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

ADUS Addus HomeCare Corpo
9.7
ENSG The Ensign Group, In
9.3
PNTG The Pennant Group, I
9.3
ARDT Ardent Health, Inc.
9.1
UHS Universal Health Ser
9.0

See full Medical Care Facilities rankings →

Valuation Divergence

Spread

4758%

Fair Value Range

$12.38 – $601.42

A 4758% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

First Chicago

$601.42 (+17.8%)

Most Bearish

Dynamic NAV

$12.38 (-97.6%)

Key Risk Factors

Model Disagreement

4758% spread signals high variance in projections.

Bearish Consensus

11/12 models suggest overvaluation.

Macro/Sector Risk

Medical Care Facilities headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CHE Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Chemed Corp at $510.42. 9/12 models flag overvaluation, composite fair value sits at $340.23 (-33.3%), and the risk-reward profile appears unfavorable. Quality at 9.1/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Chemed Corp's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy CHE stock right now?

Based on CirclFi's multi-model analysis, 1 of 12 models see upside for CHE at $510.42. The models are divided, which means the investment case depends heavily on your assumptions about Chemed Corp's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Chemed Corp?

Key risks include: wide model disagreement (4758% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.

How does CHE compare to its competitors?

Among Medical Care Facilities peers, CHE holds a Quality Score of 9.1/10. Comparable companies include ADUS (QOC 9.7), ENSG (QOC 9.3), PNTG (QOC 9.3). The relative ranking helps investors identify whether CHE offers better fundamental quality than alternatives in the same sector.

Is CHE a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CHE's Quality Score of 9.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy CHE at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $12.38 to $601.42. At $510.42, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CHE.

View CHE Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →